Hayat Pharmaceutical Industries Co (AMM:HPIC) Altman Z2-Score: 9.40 (As of Jul. 02, 2026) — 13% Below Median


AMM:HPIC Hayat Pharmaceutical Industries Co AMM:HPIC
77 GF Score
Price JOD3.13
GF Value JOD2.74
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Hayat Pharmaceutical Industries Co Altman Z2-Score?

Hayat Pharmaceutical Industries Co AMM:HPIC 77 Altman Z2-Score is 9.40 as of Jul. 02, 2026, which is 13% below its 10-year median of 10.81. GuruFocus rates AMM:HPIC with a GF Score™ of 77/100 and a GF Value™ of JOD2.74 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 995 Drug Manufacturers companies, Hayat Pharmaceutical Industries Co ranks better than 83.82% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Hayat Pharmaceutical Industries Co has a Altman Z2-Score of 9.40, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Hayat Pharmaceutical Industries Co's Altman Z2-Score or its related term are showing as below:

AMM:HPIC' s Altman Z2-Score Range Over the Past 10 Years
Min: 6.7   Med: 10.81   Max: 13.34
Current: 9.4

During the past 13 years, Hayat Pharmaceutical Industries Co's highest Altman Z2-Score was 13.34. The lowest was 6.70. And the median was 10.81.


Hayat Pharmaceutical Industries Co  (AMM:HPIC) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Hayat Pharmaceutical Industries Co Altman Z2-Score Related Terms


Hayat Pharmaceutical Industries Co Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Hayat Pharmaceutical Industries Co's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hayat Pharmaceutical Industries Co Altman Z2-Score Chart

Hayat Pharmaceutical Industries Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.21 11.65 11.10 10.20 10.34

Hayat Pharmaceutical Industries Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.95 9.66 9.16 10.34 9.40

AMM:HPIC vs ZTS, UTHR, VTRS: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hayat Pharmaceutical Industries Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hayat Pharmaceutical Industries Co Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hayat Pharmaceutical Industries Co's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Hayat Pharmaceutical Industries Co's Altman Z2-Score falls into.


AMM:HPIC
77GF Score
Hayat Pharmaceutical Industries Co AMM:HPIC
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hayat Pharmaceutical Industries Co Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Hayat Pharmaceutical Industries Co's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5357+3.26*0.3201+6.72*0.0674+1.05*4.1843
=9.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was JOD38.68 Mil.
Total Current Assets was JOD25.06 Mil.
Total Current Liabilities was JOD4.35 Mil.
Retained Earnings was JOD12.38 Mil.
Pre-Tax Income was 0.181 + 1.019 + 0.816 + 0.456 = JOD2.47 Mil.
Interest Expense was -0.031 + -0.019 + -0.051 + -0.034 = JOD-0.14 Mil.
Total Liabilities was JOD7.46 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(25.064 - 4.346)/38.675
=0.5357

X2=Retained Earnings/Total Assets
=12.381/38.675
=0.3201

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(2.472 - -0.135)/38.675
=0.0674

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(31.215 - 0)/7.46
=4.1843

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Hayat Pharmaceutical Industries Co has a Altman Z2-Score of 9.40 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 9.40 mean?
Hayat Pharmaceutical Industries Co (AMM:HPIC) has a Altman Z2-Score of 9.40 as of Jul. 02, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Hayat Pharmaceutical Industries Co and its competitors. This is 13% below median its historical median of 10.81. Over the past decade, Hayat Pharmaceutical Industries Co's Altman Z2-Score has ranged from 6.70 to 13.34. According to the industry distribution chart, Hayat Pharmaceutical Industries Co ranks #161 out of 995 companies in the Drug Manufacturers industry, placing it in the top 16.2%.
Is Hayat Pharmaceutical Industries Co's Altman Z2-Score too high?
Hayat Pharmaceutical Industries Co's current Altman Z2-Score of 9.40 is 13% below median its 10-year median of 10.81. Over the past 10 years, this metric has ranged from a low of 6.70 to a high of 13.34. The Drug Manufacturers industry median Altman Z2-Score is 3.87. Hayat Pharmaceutical Industries Co's value of 9.40 is 142.9% above this industry median. Based on the distribution chart, Hayat Pharmaceutical Industries Co ranks #161 out of 995 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hayat Pharmaceutical Industries Co has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hayat Pharmaceutical Industries Co's Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hayat Pharmaceutical Industries Co ranks #161 out of 995 companies for Altman Z2-Score. This places Hayat Pharmaceutical Industries Co in the top 16% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.87. Hayat Pharmaceutical Industries Co's value of 9.40 is 142.9% above this benchmark. Historically, Hayat Pharmaceutical Industries Co's own Altman Z2-Score has ranged from 6.70 to 13.34 over the past decade. While the company's 10-year median is 10.81 vs. the industry median of 3.87, Hayat Pharmaceutical Industries Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hayat Pharmaceutical Industries Co's current Altman Z2-Score of 9.40 is 142.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Hayat Pharmaceutical Industries Co and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hayat Pharmaceutical Industries Co's current Altman Z2-Score is 9.40, which is 13% below median its own 10-year median of 10.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hayat Pharmaceutical Industries Co stock overvalued right now?
Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co (AMM:HPIC) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD2.74, compared to a current price of JOD3.13 — trading 14.2% above its estimated fair value. The current Altman Z2-Score is 9.40, which is 13% below median its 10-year median of 10.81 and 142.9% above the Drug Manufacturers industry median of 3.87. Hayat Pharmaceutical Industries Co's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Hayat Pharmaceutical Industries Co (AMM:HPIC), the current Altman Z2-Score is 9.40 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hayat Pharmaceutical Industries Co (AMM:HPIC) Overvalued in 2026?

Based on GuruFocus' analysis, Hayat Pharmaceutical Industries Co stock appears to be overvalued. The current stock price of JOD3.13 is trading 14.2% above its estimated GF Value™ of JOD2.74. GuruFocus considers Hayat Pharmaceutical Industries Co to be Modestly Overvalued.

Key valuation signals for AMM:HPIC:

  • Altman Z2-Score: 9.40 (13% below median its 10-year median of 10.81)
  • GF Value™: JOD2.74 vs. price of JOD3.13 (14.2% above fair value)
  • GF Score™: 77/100 with 6 warning signs
  • Industry Position: 142.9% above the Drug Manufacturers median (#161 of 995)

No single metric tells the full story. See the AMM:HPIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hayat Pharmaceutical Industries Co Business Description

Address Mohammed Ali Alkurdi St. Al-Rajeeb Amman, 1564 Amman, Amman, JOR, 11118
Hayat Pharmaceutical Industries Co is a Jordan based pharmaceutical manufacturing company. The princapal activity is producing human and veterinary medicines in all its forms and medical stickers and stockings, in addition to the production of medical supplies, body care lotions, cosmetics, sutures and initiating marketing campgains as well as import and export operations. Its products include Cardiovascular system, Infectious disease, Dermatology, Gastrointestinal system, Inner Ear & Balance, Men's Health, Neurology, Vitamins & Supplements, Women's Health, and Respiratory system. The operations business operating within one geographic sector which is the Hashemite Kingdom of Jordan.
77GF Score

Get the complete analysis for AMM:HPIC

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

JOD3.13
Price
JOD2.74
GF Value